With the potential differential effect of TP53 status regarding decitabine or azacitidine therapy, it would be of great interest to investigate the accuracy of these phenotype-genotype tools in predicting the outcome of AML patients treated with decitabine. This evidence concerns the gene TP53 and acute myeloid leukemia.